GDMC
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
GDMC (Genetic Design and Manufacturing Corporation) was a Singapore biotechnology company founded in 2021, designing and manufacturing high-value genetic medicines including mRNA vaccines and therapies, plasmid DNA and viral vectors (AAV and lentiviral), as well as cell and gene therapies. It served early-stage biotech companies and research investigators in the US and Asia-Pacific with a 'design by synthetic biology' partnership model. In January 2024 it raised a $21 million Series A led by Celadon Partners, with WI Harper Group, SEEDS Capital and NSG Ventures participating, to expand operations and build a 155,000-square-foot manufacturing facility in Singapore. Just months later, in June 2024, the company filed for liquidation.
02 / GDMC FAILURE REASONS
Failure reasons
GDMC collapsed with unusual speed: it raised a $21 million Series A in January 2024 to fund an ambitious 155,000-square-foot facility, yet filed for liquidation by June 2024, with provisional liquidation proceedings reported in mid-June. The specific reasons for the collapse were never publicly disclosed, so no verified cause of failure beyond the documented sequence can be stated.
03 / EVENT HISTORY
Events in the structured record
- Liquidation
tenant GDMC Pte. Ltd. (Genetic Design and Manufacturing) placed in provisional liquidation 10 Jun 2024 with Quantuma provisional liquidators for creditors' voluntary winding up; Business Times same day. Company register later shows In Liquidation – Creditors voluntary winding up.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
In 2021 GDMC (Genetic Design and Manufacturing Corporation) was founded in Singapore, designing and manufacturing genetic medicines including mRNA, plasmid DNA, viral vectors and cell and gene therapies.
- 02
In January 2024 the company raised a $21 million Series A led by Celadon Partners, with WI Harper Group, SEEDS Capital and NSG Ventures participating, to expand operations and build a 155,000-square-foot facility in Singapore.
- 03
In June 2024, just months after the funding round, GDMC filed for liquidation; provisional liquidation proceedings were reported in mid-June 2024.
- 04
The company is recorded in Singapore's corporate registry as in creditors' voluntary liquidation.
- 05
The specific reasons for the collapse were never publicly disclosed, so no loss amount is recorded.